Barclays
TSHA icon

Barclays’s Taysha Gene Therapies TSHA Stock Holding History

Barclays’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Sell
1,630,659
-1,181,351
-42% -$6.99M ﹤0.01% 1428
2026
Q1 		$11.4M Sell
2,812,010
-2,726,991
-49% -$12.7M ﹤0.01% 1384
2025
Q4 		$30.5M Buy
5,539,001
+390,889
+8% +$1.9M 0.01% 1016
2025
Q3 		$16.8M Buy
5,148,112
+4,697,611
+1,043% +$13.3M ﹤0.01% 1327
2025
Q2 		$1.04M Sell
450,501
-258,465
-36% -$562K ﹤0.01% 3312
2025
Q1 		$985K Buy
708,966
+373,728
+111% +$625K ﹤0.01% 3118
2024
Q4 		$587K Buy
335,238
+87,958
+36% +$182K ﹤0.01% 3727
2024
Q3 		$512K Buy
247,280
+193,046
+356% +$424K ﹤0.01% 3761
2024
Q2 		$117K Buy
+54,234
New +$158K ﹤0.01% 3830
2023
Q1 		– Sell
-44,013
Closed -$96.8K – 5355
2022
Q4 		$96.8K Sell
44,013
-3,866
-8% -$7.83K ﹤0.01% 4244
2022
Q3 		$97K Hold
47,879
– – ﹤0.01% 3553
2022
Q2 		$184K Buy
47,879
+3,492
+8% +$13.9K ﹤0.01% 3479
2022
Q1 		$273K Buy
+44,387
New +$332K ﹤0.01% 3248

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's TSHA Position: Q2 2026 in Review

Barclays reduced its Taysha Gene Therapies (TSHA) stake by 42% in Q2 2026, selling an estimated $6.99M and leaving 1,630,659 shares worth $11.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1428.

Barclays first reported a position in TSHA in Q1 2022 and has held it in 13 quarters since. The position peaked at $30.5M in Q4 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Barclays held 1,630,659 shares of Taysha Gene Therapies worth $11.1M as of Q2 2026.
  • Barclays sold 1,181,351 Taysha Gene Therapies shares in Q2 2026, an estimated $6.99M.
  • Taysha Gene Therapies made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1428 holding.
  • Barclays first reported a position in Taysha Gene Therapies in Q1 2022 and has held it in 13 quarters since.
  • Barclays's Taysha Gene Therapies position peaked at $30.5M in Q4 2025.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.